CD8A and cancer: Unlike the theory behind cancer T-cell immunotherapy, it is unclear whether simply supplying more HIV-specific CD8+ T cells would necessarily provide better control of virus replication due to shortcomings of the HIV-reactive T cells themselves or the seemingly inexhaustible ability of HIV to escape the immune response by mutation [33], [34], [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47].